Cyclica Appoints Renowned Healthcare AI Executive, Sastry Chilukuri, to Board of Directors to Help Build the Biotech Pipeline of the Future

NEW YORK & TORONTO–(BUSINESS WIRE)–Cyclica announced the election of Sastry Chilukuri to its Board of Directors effective immediately. Chilukuri was also appointed to the Compensation and Governance sub-committees.

Chilukuri, a health technology thought leader, is currently President of Acorn AI and EVP of Medidata, a Dassault Systèmes company. From 2006-2018, he was a partner at McKinsey & Company serving pharmaceutical, medical device, technology and public sector clients. Prior to that, he served in global product engineering roles at GE Healthcare launching imaging and health IT products. Chilukuri holds a Masters in Management degree from the Kellogg Graduate School of Management, Northwestern University; a Bachelor of Technology degree in Engineering from the Indian Institute of Technology (IIT).

Cyclica, the partner of choice for data-driven drug discovery, who advance molecules that embrace the complexity of disease, announced their plans to create the biotech pipeline of the future with their Series B round of financing. With Chilukuri’s experience, the timing of his appointment is impeccable, indicates Naheed Kurji, CEO, President and Co-Founder of Cyclica. “Sastry’s experience helping life science leaders grow and innovate through technology disruption will help us revolutionize drug discovery and advance our mission of bringing precision medicine to patients, faster,” says Kurji.

Chilukuri shares his enthusiasm for his appointment to Cyclica’s Board of Directors by adding that “Just as the collaboration between biologists and chemists revolutionized the discovery of biologics, I believe we are at a tipping point for small molecule discovery using data science and AI. Cyclica’s polypharmacology approach to drug discovery is unique and I look forward to helping change patients’ lives with them.”

About Cyclica

Cyclica is the partner of choice for data-driven drug discovery. We advance molecules that embrace the complexity of disease. Our work spans dozens of collaborations with large pharma and biotech as well as 50 joint ventures and counting. We are a passionate team of biotech and pharma professionals, biologists, chemists, and computer scientists who live and labor at the intersection of our collective expertise.

To learn more about Cyclica and how we partner, please visit


Jennifer Sacco

error: Content is protected !!